(MCRI) Monarch Casino & Resort - Overview
Stock: Casino, Hotel, Spa, Resort
EPS (Earnings per Share)
Revenue
Dividends
| Dividend Yield | 1.29% |
| Yield on Cost 5y | 2.90% |
| Yield CAGR 5y | -54.90% |
| Payout Consistency | 78.6% |
| Payout Ratio | 20.9% |
| Risk 5d forecast | |
|---|---|
| Volatility | 22.6% |
| Relative Tail Risk | -8.92% |
| Reward TTM | |
|---|---|
| Sharpe Ratio | 0.48 |
| Alpha | 4.00 |
| Character TTM | |
|---|---|
| Beta | 0.672 |
| Beta Downside | 0.698 |
| Drawdowns 3y | |
|---|---|
| Max DD | 23.68% |
| CAGR/Max DD | 0.52 |
Description: MCRI Monarch Casino & Resort January 15, 2026
Monarch Casino & Resort, Inc. (NASDAQ:MCRI) operates two full-service casino-hotel properties: the Atlantis Casino Resort Spa in Reno, Nevada, and the Monarch Casino Resort Spa Black Hawk in Colorado. Both assets combine gaming floors, hotel rooms, food-and-beverage outlets, and spa amenities, and the firm also holds undeveloped parcels of land adjacent to its operating sites. The company was incorporated in 1993 and remains headquartered in Reno.
Key performance indicators that typically drive valuation in this niche include same-store gaming revenue growth, hotel RevPAR (revenue per available room), and occupancy rates. In Q4 2023, the Reno property reported a 7.2 % year-over-year increase in gaming win per unit, while Black Hawk’s hotel RevPAR rose to $115, reflecting a rebound in domestic leisure travel after the pandemic-induced slump. Macro-level drivers remain discretionary consumer spending and regional tourism flows, which are sensitive to employment trends in Nevada and Colorado and to broader macro-economic variables such as interest-rate-driven disposable-income changes.
For a deeper quantitative breakdown and scenario analysis, you may find the ValueRay platform useful as a next step in your research.
Piotroski VR‑10 (Strict, 0-10) 7.5
| Net Income: 101.4m TTM > 0 and > 6% of Revenue |
| FCF/TA: 0.17 > 0.02 and ΔFCF/TA 7.16 > 1.0 |
| NWC/Revenue: -3.84% < 20% (prev -10.73%; Δ 6.89% < -1%) |
| CFO/TA 0.23 > 3% & CFO 164.4m > Net Income 101.4m |
| Net Debt (-83.2m) to EBITDA (170.7m): -0.49 < 3 |
| Current Ratio: 0.86 > 1.5 & < 3 |
| Outstanding Shares: last quarter (18.7m) vs 12m ago -0.12% < -2% |
| Gross Margin: 64.52% > 18% (prev 0.51%; Δ 6400 % > 0.5%) |
| Asset Turnover: 77.63% > 50% (prev 75.51%; Δ 2.12% > 0%) |
| Interest Coverage Ratio: 60.26 > 6 (EBITDA TTM 170.7m / Interest Expense TTM 1.94m) |
Altman Z'' 7.24
| A: -0.03 (Total Current Assets 129.3m - Total Current Liabilities 150.2m) / Total Assets 712.8m |
| B: 0.84 (Retained Earnings 597.8m / Total Assets 712.8m) |
| C: 0.17 (EBIT TTM 116.7m / Avg Total Assets 702.2m) |
| D: 3.41 (Book Value of Equity 598.0m / Total Liabilities 175.2m) |
| Altman-Z'' Score: 7.24 = AAA |
Beneish M -3.35
| DSRI: 0.90 (Receivables 11.1m/11.8m, Revenue 545.1m/522.2m) |
| GMI: 0.80 (GM 64.52% / 51.39%) |
| AQI: 1.01 (AQ_t 0.04 / AQ_t-1 0.04) |
| SGI: 1.04 (Revenue 545.1m / 522.2m) |
| TATA: -0.09 (NI 101.4m - CFO 164.4m) / TA 712.8m) |
| Beneish M-Score: -3.35 (Cap -4..+1) = AA |
What is the price of MCRI shares?
Over the past week, the price has changed by +7.56%, over one month by +5.07%, over three months by +4.85% and over the past year by +17.26%.
Is MCRI a buy, sell or hold?
- StrongBuy: 1
- Buy: 0
- Hold: 3
- Sell: 0
- StrongSell: 1
What are the forecasts/targets for the MCRI price?
| Issuer | Target | Up/Down from current |
|---|---|---|
| Wallstreet Target Price | 107.7 | 8.9% |
| Analysts Target Price | 107.7 | 8.9% |
| ValueRay Target Price | 109.2 | 10.4% |
MCRI Fundamental Data Overview February 09, 2026
P/E Forward = 17.1233
P/S = 3.3101
P/B = 3.2767
P/EG = 1.89
Revenue TTM = 545.1m USD
EBIT TTM = 116.7m USD
EBITDA TTM = 170.7m USD
Long Term Debt = 12.3m USD (estimated: total debt 13.3m - short term 1.02m)
Short Term Debt = 1.02m USD (from shortTermDebt, last quarter)
Debt = 13.3m USD (from shortLongTermDebtTotal, last quarter)
Net Debt = -83.2m USD (from netDebt column, last quarter)
Enterprise Value = 1.72b USD (1.80b + Debt 13.3m - CCE 96.5m)
Interest Coverage Ratio = 60.26 (Ebit TTM 116.7m / Interest Expense TTM 1.94m)
EV/FCF = 14.06x (Enterprise Value 1.72b / FCF TTM 122.5m)
FCF Yield = 7.11% (FCF TTM 122.5m / Enterprise Value 1.72b)
FCF Margin = 22.46% (FCF TTM 122.5m / Revenue TTM 545.1m)
Net Margin = 18.60% (Net Income TTM 101.4m / Revenue TTM 545.1m)
Gross Margin = 64.52% ((Revenue TTM 545.1m - Cost of Revenue TTM 193.4m) / Revenue TTM)
Gross Margin QoQ = none% (prev 46.37%)
Tobins Q-Ratio = 2.41 (Enterprise Value 1.72b / Total Assets 712.8m)
Interest Expense / Debt = 4.92% (Interest Expense 654.0k / Debt 13.3m)
Taxrate = 21.0% (US default 21%)
NOPAT = 92.2m (EBIT 116.7m * (1 - 21.00%))
Current Ratio = 0.86 (Total Current Assets 129.3m / Total Current Liabilities 150.2m)
Debt / Equity = 0.02 (Debt 13.3m / totalStockholderEquity, last quarter 537.7m)
Debt / EBITDA = -0.49 (Net Debt -83.2m / EBITDA 170.7m)
Debt / FCF = -0.68 (Net Debt -83.2m / FCF TTM 122.5m)
Total Stockholder Equity = 542.7m (last 4 quarters mean from totalStockholderEquity)
RoA = 14.44% (Net Income 101.4m / Total Assets 712.8m)
RoE = 18.68% (Net Income TTM 101.4m / Total Stockholder Equity 542.7m)
RoCE = 21.03% (EBIT 116.7m / Capital Employed (Equity 542.7m + L.T.Debt 12.3m))
RoIC = 16.94% (NOPAT 92.2m / Invested Capital 544.4m)
WACC = 8.36% (E(1.80b)/V(1.82b) * Re(8.39%) + D(13.3m)/V(1.82b) * Rd(4.92%) * (1-Tc(0.21)))
Discount Rate = 8.39% (= CAPM, Blume Beta Adj.)
Shares Correlation 3-Years: -100.0 | Cagr: -2.22%
[DCF Debug] Terminal Value 79.96% ; FCFF base≈101.2m ; Y1≈123.5m ; Y5≈205.4m
Fair Price DCF = 186.6 (EV 3.24b - Net Debt -83.2m = Equity 3.33b / Shares 17.8m; r=8.36% [WACC]; 5y FCF grow 23.62% → 2.90% )
EPS Correlation: 63.09 | EPS CAGR: 14.92% | SUE: 1.24 | # QB: 1
Revenue Correlation: 77.50 | Revenue CAGR: 7.08% | SUE: 0.15 | # QB: 0
EPS next Quarter (2026-03-31): EPS=1.16 | Chg30d=+0.017 | Revisions Net=+0 | Analysts=2
EPS current Year (2026-12-31): EPS=5.80 | Chg30d=+0.032 | Revisions Net=+0 | Growth EPS=-0.2% | Growth Revenue=+2.8%
EPS next Year (2027-12-31): EPS=5.95 | Chg30d=-0.038 | Revisions Net=+0 | Growth EPS=+2.4% | Growth Revenue=+2.2%